Electrophysiology and optical coherence tomography to evaluate parkinson disease severity

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 2, 2014, Pages 696-705

  Garcia Martin, Elena ^a,b   Rodriguez Mena, Diego ^a,b   Satue, Maria ^a,b   Almarcegui, Carmen ^a,b   Dolz, Isabel ^a,b   Alarcia, Raquel ^a,b   Seral, Maria ^a,b   Polo, Vicente ^a,b   Larrosa, Jose M ^a,b   Pablo, Luis E ^a,b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

Optical coherence tomography; Parkinson disease; Pattern electroretinogram; Quality of life; Visual evoked potentials

Indexed keywords

AMITRIPTYLINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; PRAMIPEXOLE; PROPRANOLOL; RASAGILINE; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; ELECTROPHYSIOLOGY; EVOKED VISUAL RESPONSE; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RETINA FOVEA; RETINAL NERVE FIBER LAYER THICKNESS; VISUAL ACUITY;

OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PATTERN ELECTRORETINOGRAM; QUALITY OF LIFE; VISUAL EVOKED POTENTIALS;

AGED; AGED, 80 AND OVER; AXONS; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; RETINAL GANGLION CELLS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELDS;

EID: 84893326412     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13062     Document Type: Article

References (51)

1. Dae-Hyuk K, Jong-Min K, Se-Hong O, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol. 2012;71:267-277.
2. Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011;10:509-519.
3. Schraermeyer U, Kopitz J, Peters S, et al. Tyrosinase biosynthesis in adult mammalian retinal pigment epithelial cells. Exp Eye Res. 2006;83:315-321.
4. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol. 2009;127: 737-741.
5. Altintaş O, Işeri P, Ozkan B, Caǧlar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol. 2008;116: 137-146.
6. Satue M, Garcia-Martin E, Fuertes I, et al. Use of Fourierdomain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. Eye. 2013;27:507-514.
7. Garcia-Martin E, Satue M, Fuertes I, et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. Ophthalmology. 2012;119:2161-2167.
8. Garcia-Martin E, Pablo LE, Herrero R, et al. Diagnostic ability of a linear discriminant function for Spectral domain optical coherence tomography in multiple sclerosis patients. Ophthalmology. 2012;119:1705-1711.
9. Seigo MA, Sotirchos ES, Newsome S, et al. In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. J Neurol. 2012;259:2119-2130.
10. Garcia-Martin E, Pinilla I, Sancho E, et al. OCT in retinitis pigmentosa: reproducibility and capacity to detect macular and retinal nerve fiber layer thickness alterations. Retina. 2012;32:1581-1591.
11. Bodis-Wollner I. Retinopathy in Parkinson Disease. J Neural Transm. 2009;116:1493-1501.
12. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology. 1992;42:887-890.
13. Rodriguez-Mena D, Almarcegui C, Dolz I, et al. Electrophysiologic evaluation of the visual pathway in patients with multiple sclerosis. J Clinical Neurophysiol. 2012;87:311-314.
14. Gołab M, Fabian A, Honczarenko K. Significance of visual evoked potentials (VEP) in the diagnosis of Parkinson disease [in Polish]. Neurol Neurochir Pol. 2003;37(suppl 5):145-154.
15. Sartucci F, Orlandi G, Bonuccelli U, et al. Chromatic patternreversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease. Neurol Sci. 2006;26:395-401.
16. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol. 1996;100:1-11.
17. Almarcegui C, Dolz I, Pueyo V, et al. Correlation between functional and structural assessments of the optic nerve and retina in multiple sclerosis patients. Neurophysiol Clin. 2010; 40:129-135.
18. Holder GE. The pattern electroretinogram. In: Heckenlively R, Arden GB, eds. Principles and Practice of Clinical Electrophysiology of Vision. 2nd ed. Cambridge: MIT Press; 2006: 341-345.
19. Corallo G, Cicinelli S, Papadia M, et al. Conventional perimetry, short-wavelength automated perimetry, frequency-doubling technology, and visual evoked potentials in the assessment of patients with multiple sclerosis. Eur J Ophthalmol. 2005;15: 730-738.
20. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuroophthalmologic evaluation, quality of life and functional disability in patients with MS. Neurology. 2013;81:76-83.
21. Opara J, Brola W, Leonardi M, Błaszczyk B. Quality of life in Parkinson's disease. J Med Life. 2012;5:375-381.
22. Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology. 2013;80:409-416.
23. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027-3034.
24. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
25. Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. The movement disorder society task force on rating scales for Parkinson's disease. Mov Dis. 2004;19:1020-1028.
26. Gillingham FJ, Donaldson MC, eds. Schwab and England Activities of Daily Living. Third Symposium of Parkinson's Disease. Edinburgh, Scotland: E&S Livingstone; 1969:152-157.
27. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology. 2007;68:1488-1494.
28. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol. 1993;111:831-836.
29. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-376.
30. Heijl A, Lindgren A, Lindgren G. Test-retest variability in glaucomatous visual fields. Am J Ophthalmol. 1989;108:130-135.
31. Chin EK, Sedeek RW, Li Y, et al. Reproducibility of macular thickness measurement among five OCT instruments: effects of image resolution, image registration, and eye tracking. Ophthalmic Surg Lasers Imaging. 2013;43:97-108.
32. Garcia-Martin E, Pinilla I, Idoipe M, et al. Intra and interoperator reproducibility of retinal nerve fibre and macular thickness measurements using Cirrus Fourier-domain OCT. Acta Ophthalmol. 2011;89:e23-e29.
33. Holder GE, Brigell MG, Hawlina M, et al. International society for clinical electrophysiology of vision. ISCEV standard for clinical pattern electroretinography-2007 update. Doc Ophthalmol. 2007;114:111-116.
34. Dawson WW, Trick GL, Litzkow CA. Improved electrode for electroretinography. Invest Ophthalmol Vis Sci. 1979;18:988-991.
35. Sikk K, Haldre S, Aquilonius SM, et al. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol. 2013;20:915-920.
36. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain. 2009;132(pt 5):1128-1145.
37. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat. 1988;10: 137-144.
38. Joo HR, Peterson BB, Dacey DM, Hattar S, Chen SK. Recurrent axon collaterals of intrinsically photosensitive retinal ganglion cells. Vis Neurosci. 2013;30:175-182.
39. La Morgia C, Barboni P, Rizzo G, et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur J Neurol. 2013;20:198-201.
40. Aaker GD, Myung JS, Ehrlich JR, et al. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol. 2010;4:1427-1432.
41. Jindahra P, Petrie A, Plant GT. Retrograde trans-synaptic retinal ganglion cell loss identified by optical coherence tomography. Brain. 2009;132:628-634.
42. Reich DS, Smith SA, Gordon-Lipkin EM, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. 2009;66:998-1006.
43. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004;44: 2793-2797.
44. Spund B, Ding Y, Liu T, et al. Remodeling of the fovea in Parkinson disease. J Neural Transm. 2013;120:745-753.
45. May JG, Ralton J, Reed JL, Van Dyk HL. Loss in pattern-elicited electroretinograms in optic disc nerve dysfunction. Am J Ophthalmol. 1982;93:418-422.
46. Peppe A, Stanzione P, Pierelli F, et al. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology. 1995;45:1144-1148.
47. Bodis-Wollner I, Yahr MD, Thornton J. Visual evoked potentials and the severity of Parkinson's disease. In: Rose C, Capildeo R, eds. Research Progress in Parkinson's Disease. Tunbridge Wells: Pitman Medical; 1981:126-137.
48. Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480:547-551.
49. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/ carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68: 18-27.
50. Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011;10:509-519.
51. Garcia-Martin E, Pueyo V, Pinilla I, et al. Fourier-domain OCT in multiple sclerosis patients: reproducibility and ability to detect retinal nerve fiber layer atrophy. Invest Ophthalmol Vis Sci. 2011;52:4124-4131.